Aldeyra Therapeutics Inc (NAS:ALDX)
$ 3.91 0.12 (3.17%) Market Cap: 232.31 Mil Enterprise Value: 114.93 Mil PE Ratio: 0 PB Ratio: 2.05 GF Score: 43/100

Aldeyra Therapeutics Inc Corporate Analyst Meeting Transcript

Feb 24, 2020 / 05:00PM GMT
Release Date Price: $4.84 (-4.16%)
Todd C. Brady
Aldeyra Therapeutics, Inc. - CEO, President & Director

Okay. Thank you all for joining us today. It's great to see so many of you here. Those of you that know me know that I take great pleasure in R&D days. They allow us to talk about data in ways that we don't typically talk about in standard data releases and press releases and so forth. And there's a lot going on at Aldeyra, as many of you know. And so we're thrilled to be here today and thank you all for coming. And for those of you that are on the webcast, we appreciate your listening in as well.

As always, we do have a forward-looking statement slide, which I encourage you to review, which I will get to when I figure out how to advance the slides here. Good. There we are. Great.

It's hard to believe that some years ago, this company started based on a novel pharmacologic target called RASP. No drugs, no animal models, just an idea and RASP was broadly applicable. And now today, RASP, thanks to the success at Aldeyra, is the subject of numerous Phase III trials. And as of last year, we acquired another

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot